➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for SGI-110

Email this page to a colleague

« Back to Dashboard

What is the drug development status for SGI-110?

SGI-110 is an investigational drug.

There have been 30 clinical trials for SGI-110. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Preleukemia. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are twenty US patents protecting this investigational drug and one hundred and fifty-four international patents.

Recent Clinical Trials for SGI-110
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Astex Pharmaceuticals, Inc.Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Bristol-Myers SquibbPhase 2

See all SGI-110 clinical trials

Clinical Trial Summary for SGI-110

Top disease conditions for SGI-110
Top clinical trial sponsors for SGI-110

See all SGI-110 clinical trials

US Patents for SGI-110

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGI-110   Try Before You Buy Using DNA methyltransferase inhibitors to treat calcific aorta valve disease Mayo Foundation for Medical Education and Research (Rochester, MN)   Try Before You Buy
SGI-110   Try Before You Buy Nucleotides for the treatment of liver cancer IDENIX PHARMACEUTICALS LLC (Cambridge, MA)   Try Before You Buy
SGI-110   Try Before You Buy Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD) THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.